1 Min Read
Feb 3 (Reuters) - Swedish Orphan Biovitrum
* Says confirms that company is in discussions with a private equity firm regarding a possible sale of its partner products business area excluding Kineret and Orfadin.
* Says discussions may or may not lead to an agreement
* "We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement", said Geoffrey McDonough, CEO and President
* Trade in the Sobi share was suspended at 13:16 GMT Source text for Eikon: Further company coverage: (Stockholm Newsroom)